阿达木单抗治疗难治性青斑样血管病2例

doi:10.35541/cjd.20220532

Chinese Journal of Dermatology ›› 2025, e20220532.doi: 10.35541/cjd.20220532

• Case Reports • Previous Articles Next Articles

Two cases of refractory livedoid vasculitis successfully treated with adalimumab

Li Qian¹, Dong Liangjiao², Yu Yihui³, Xue Rujun¹, Liang Jingyao¹, Zhang Xibao¹

¹Department of Dermatology, Institute of Dermatology, Guangzhou Medical University, Guangzhou Dermatology Hospital, Guangzhou 510095, China; ²Department of Dermatology, Shunde District Third People's Hospital, Foshan 528300, Guangdong, China; ³Department of Dermatology, Guangdong Second People's Hospital，Guangzhou 510317, China

Received:2022-07-29 Revised:2024-12-16 Online:2025-01-10 Published:2025-09-22
Contact: Zhang Xibao E-mail:gzpfbfzs@163.com
Supported by:
Science and Technology Program of Guangzhou（2023A03J0472）

Abstract

Li Qian, Dong Liangjiao, Yu Yihui, Xue Rujun, Liang Jingyao, Zhang Xibao. Two cases of refractory livedoid vasculitis successfully treated with adalimumab[J]. Chinese Journal of Dermatology,2025,e20220532. doi:10.35541/cjd.20220532

References ［10］

［1］	Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: a review of pathogenesis and principles of management［J］. Indian J Dermatol Venereol Leprol, 2016,82（5）:478⁃488. doi: 10.4103/0378⁃6323.183635.
［2］	Lee JS, Cho S. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment［J］. J Eur Acad Dermatol Venereol, 2020,34（4）:e176⁃e178. doi: 10.1111/jdv. 16129.
［3］	Rujitharanawong C, Chularojanamontri L, Trakanwittayarak S, et al. Livedoid vasculopathy: clinical course and long⁃term outcome in Asian patients with a review of the literature［J］. Dermatol Ther, 2021,34（1）:e14569. doi: 10.1111/dth.14569.
［4］	Huang XW, Zheng HX, Wang ML, et al. Adalimumab in treating refractory livedoid vasculopathy［J］. Vaccines （Basel）, 2022,10（4）:549. doi: 10.3390/vaccines10040549.
［5］	Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF⁃α and complement component 3 on coagulation［J］. Sci Rep, 2018,8（1）:1812. doi: 10.1038/s41598⁃018⁃20220⁃8.
［6］	Manfredi AA, Baldini M, Camera M, et al. Anti⁃TNFα agents curb platelet activation in patients with rheumatoid arthritis［J］. Ann Rheum Dis, 2016,75（8）:1511⁃1520. doi: 10.1136/annrheumdis⁃ 2015⁃208442.
［7］	Ueda A, Takeno M, Ishigatsubo Y. Adalimumab in the management of Behçet's disease［J］. Ther Clin Risk Manag, 2015,11:611⁃619. doi: 10.2147/TCRM.S56163.
［8］	Koberová R, Merglová V, Radochová V. Recurrent aphthous stomatitis in children: a practical guideline for paediatric practitioners［J］. Acta Medica （Hradec Kralove）, 2020,63（4）:145⁃149. doi: 10.14712/18059694.2020.56.
［9］	Gao Y, Jin H. Efficacy of an anti⁃TNF⁃alpha agent in refractory livedoid vasculopathy: a retrospective analysis［J］. J Dermatolog Treat, 2022,33（1）:178⁃183. doi: 10.1080/09546634.2020.173 7634.
［10］	Bilgic A, Ozcobanoglu S, Bozca BC, et al. Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management［J］. Int J Womens Dermatol, 2021,7（5Part A）:588⁃599. doi: 10.1016/j.ijwd.2021.08.013.

Two cases of refractory livedoid vasculitis successfully treated with adalimumab

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［10］

Related Articles 0

Metrics

Comments

Recommended 10